Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

CASE STUDY: Myriad stands alone

Nature Biotechnology volume 32, page 620 (2014)Cite this article

Subjects

Myriad took no prisoners on its way to the top of the molecular diagnostics field. That strategy is unlikely to endure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Author notes

  1. Christopher Scott: Christopher Scott is Contributing Editor, Nature Biotechnology.

Authors and Affiliations

  1. Jacob S. Sherkow is at New York Law School.,

    Jacob S Sherkow

Authors
  1. Jacob S Sherkow
    View author publications

    Search author on:PubMed Google Scholar

  2. Christopher Scott
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sherkow, J., Scott, C. CASE STUDY: Myriad stands alone. Nat Biotechnol 32, 620 (2014). https://doi.org/10.1038/nbt.2944

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt.2944

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research